Daniel Hassan

Dr. Daniel Hassan

University of Kwa-Zulu Natal Durban
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
SSSima Singh
Sima Singh
DHDaniel Hassan
Daniel Hassan
HAHibah M. Aldawsari
Hibah M. Aldawsari
NMNagashekhara Molugulu
Nagashekhara Molugulu
RSRahul Shukla
Rahul Shukla
PKPrashant Kesharwani
Prashant Kesharwani

8 October 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RMRuma Maji
Ruma Maji
COCalvin Omolo
Calvin Omolo
NANikhil Agrawal
Nikhil Agrawal
KMKaminee Maduray
Kaminee Maduray
DHDaniel Hassan
Daniel Hassan
TGThirumala Govender
Thirumala Govender

1 March 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
DHDaniel Hassan
Daniel Hassan
COCalvin Omolo
Calvin Omolo
VFVictoria Oluwaseun Fasiku
Victoria Oluwaseun Fasiku
CMChunderika Mocktar
Chunderika Mocktar
TGThirumala Govender
Thirumala Govender

1 March 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DHDaniel Hassan
Daniel Hassan
COCalvin Omolo
Calvin Omolo
RGRamesh Gannimani
Ramesh Gannimani
Ayman WaddadAyman Waddad
Ayman Waddad
CMChunderika Mocktar
Chunderika Mocktar
TGThirumala Govender
Thirumala Govender

14 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DHDaniel Hassan
Daniel Hassan
COCalvin Omolo
Calvin Omolo
VFVictoria Oluwaseun Fasiku
Victoria Oluwaseun Fasiku
AEAhmed A. El-Rashedy
Ahmed A. El-Rashedy
CMChunderika Mocktar
Chunderika Mocktar
TGThirumala Govender
Thirumala Govender
Globally, human beings continue to be at high risk of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA); and current treatments are being depleted due to antimicrobial resistance. Therefore, the synthesis and formulation of novel materials is essential for combating antimicrobial resistance. The study aimed to synthesize a quaternary bicephalic surfactant (StBAclm) and thereof to formulate pH-responsive vancomycin (VCM)-loaded quatsomes to enhance the activity of the antibiotic against MRSA. The surfactant structure was confirmed using 1H, 13C nuclear magnetic resonance (NMR), Fourier-transform infrared spectroscopy (FT-IR), and high-resolution mass spectrometry (HRMS). The quatsomes were prepared using a sonication/dispersion method and were characterized using various in vitro, in vivo, and in silico techniques. The in vitro cell biocompatibility studies of the surfactant and pH-responsive vancomycin-loaded quatsomes (VCM-StBAclm-Qt1) revealed that they are biosafe. The prepared quatsomes had a mean hydrodynamic diameter (MHD), polydispersity index (PDI), and drug encapsulation efficiency (DEE) of 122.9 ± 3.78 nm, 0.169 ± 0.02 mV, and 52.22 ± 8.4%, respectively, with surface charge switching from negative to positive at pH 7.4 and pH 6.0, respectively. High-resolution transmission electron microscopy (HR-TEM) characterization of the quatsomes showed spherical vesicles with MHD similar to the one obtained from the zeta-sizer. The in vitro drug release of VCM from the quatsomes was faster at pH 6.0 compared to pH 7.4. The minimum inhibitory concentration (MIC) of the drug loaded quatsomes against MRSA was 32-fold and 8-fold lower at pH 6.0 and pH 7.4, respectively, compared to bare VCM, demonstrating the pH-responsiveness of the quatsomes and the enhanced activity of VCM at acidic pH. The drug-loaded quatsomes demonstrated higher electrical conductivity and a decrease in protein and deoxyribonucleic acid (DNA) concentrations as compared to the bare drug. This confirmed greater MRSA membrane damage, compared to treatment with bare VCM. The flow cytometry study showed that the drug-loaded quatsomes had a similar bactericidal killing effect on MRSA despite a lower (8-fold) VCM concentration when compared to the bare VCM. Fluorescence microscopy revealed the ability of the drug-loaded quatsomes to eradicate MRSA biofilms. The in vivo studies in a skin infection mice model showed that groups treated with VCM-loaded quatsomes had a 13-fold decrease in MRSA CFUs when compared to the bare VCM treated groups. This study confirmed the potential of pH-responsive VCM-StBAclm quatsomes as an effective delivery system for targeted delivery and for enhancing the activity of antibiotics.

1 November 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
COCalvin Omolo
Calvin Omolo
DHDaniel Hassan
Daniel Hassan
NDNikita Devnarain
Nikita Devnarain
YJYajna Jaglal
Yajna Jaglal
CMChunderika Mocktar
Chunderika Mocktar
TGThirumala Govender
Thirumala Govender